via University of Southampton
Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
This work, published in the journal Cancer Cell, focuses on a molecule called CD40 which is present on the surface of immune cells and controls both autoimmunity and cancer. In autoimmunity, CD40 is thought to be over-stimulated, increasing the chance of the immune system attacking healthy tissues; whereas in cancer, CD40 is believed to be under-stimulated, enabling tumour cells to evade the immune system. Targeting of CD40 with antibody drugs is ongoing in therapeutic interventions for both diseases.
Accordingly, antibody drugs have been developed to either activate (agonists) or suppress (antagonists) the CD40 immune pathway. Researchers at the Centre for Cancer Immunology in Southampton, led by Professors Mark Cragg and Martin Glennie now reveal that an antagonist CD40 antibody can be transformed into an agonist by simply modifying the “constant” domain of the antibody. The antagonist-turned agonist “trick” was shown for three different antagonists, being driven by the hinge part of the constant domain that controls the flexibility of the antibody. One of these antibodies, was shown to be a “super”-agonist that could stimulate the immune system and cure cancer more effectively in preclinical models than the best CD40-targeting antibody currently in clinical trial.
“Being able to toggle between an autoimmune drug and a cancer medicine with a simple switch is really exciting.” said Dr Xiaojie Yu, first author of the study. “We gained a deeper understanding of the mechanism through which CD40 becomes activated, and eagerly look forward to applying this technology to more drug candidates.”
“Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure,” said Professor Mark Cragg, senior author of the study. “Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future”.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Bio-orthogonally catalyzed lethality strategy generates targeting drugs from within tumorson January 25, 2021 at 11:49 am
Cancer is the second leading cause of death in the world. The number of deaths and incidences is increasing each year. The metal-based anticancer drugs were used clinically worldwide, but suffer from ...
- Bioorthogonally catalyzed lethality strategy generates targeting drugs within tumoron January 25, 2021 at 11:05 am
Ru-rhein exhibits high anti-cancer activity, especially towards lung cancer cell ... The BCL method provides a general strategy for precise diseases treatment, and also reveals that tumor can provide ...
- Naturally-Derived Compounds Have Anti-Cancer Properties that Could Help Millionson January 25, 2021 at 5:52 am
Naturally derived compounds may be useful the treatment of cancer, neurological, inflammatory, and infectious diseases. One of those is Cepharanthine (CEP), which according to Phytomedicine is a drug ...
- New drug combination shows promise as treatment for form of leukemia, La Jolla scientists sayon January 21, 2021 at 2:00 pm
Scientists at Sanford Burnham Prebys Medical Discovery Institute in La Jolla have identified two drugs that are potent when combined against acute myeloid leukemia but only partially effective when ...
- Target of new cancer treatment valid for breast as well as blood cancerson January 21, 2021 at 8:22 am
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Budweiser joins Coke, Pepsi brands in sitting out Super Bowlon January 25, 2021 at 3:04 am
Busch used all of its ad time to introduce a beer called Bud Light, the beer giant isn't advertising its iconic Budweiser brand during the Super Bowl. Instead, it’s donating the money it would have ...
- Hopes and expectation for the new presidenton January 23, 2021 at 9:00 pm
The inauguration of a new president has caused me to pause to muse about what I consider the qualities and characteristics I am looking for, not only in a president, but also a governor, a mayor or ...
- Bill seeks to ease limits on North Dakota's 'castle' lawon January 22, 2021 at 8:00 am
BISMARCK, N.D. (AP) — Far-right members of the North Dakota Legislature are taking another shot at easing restrictions on citizens' right to use deadly force in self-defense.
- New Approaches for the Treatment of Lupus Nephritis in the 21st Centuryon January 20, 2021 at 4:00 pm
In contrast to the positive signal of CD28/B7 or CD40–CD40L, ligation of PD1 on lymphocytes inhibits B- and T-cell proliferation and cytokine synthesis. PD1 and PDL1 interactions are essential ...
- Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets’ Seventeenth ...on January 19, 2021 at 3:31 pm
(GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing ...